Short-term surgical outcomes of laparoscopy-assisted versus open D2 distal gastrectomy for locally advanced gastric cancer in North China: a multicenter randomized controlled trial

Zaozao Wang¹ · Jiadi Xing¹ · Jun Cai² · Zhongtao Zhang² · Fei Li³ · Nengwei Zhang⁴ · Jixiang Wu⁵ · Ming Cui¹ · Ying Liu¹ · Lei Chen¹ · Hong Yang¹ · Zhi Zheng² · Xiaohui Wang³ · Chongchong Gao³ · Zhe Wang³ · Qing Fan⁴ · Yanlei Zhu⁴ · Shulin Ren⁵ · Chenghai Zhang¹ · Maoxing Liu³ · Jiafu Ji⁶ · Xiangqian Su¹

Received: 13 February 2018 / Accepted: 20 August 2018 / Published online: 1 November 2018
© The Author(s) 2018

Abstract

Background Although laparoscopic surgery has been recommended as an optional therapy for patients with early gastric cancer, whether patients with locally advanced gastric cancer (AGC) could benefit from laparoscopy-assisted distal gastrectomy (LADG) with D2 lymphadenectomy remains elusive due to a lack of comprehensive clinical data. To evaluate the efficacy of LADG, we conducted a multi-institutional randomized controlled trial to compare laparoscopy-assisted versus open distal gastrectomy (ODG) for AGC in North China.

Methods In this RCT, after patients were enrolled according to the eligibility criteria, they were preoperatively assigned to LADG or ODG arm randomly with a 1:1 allocation ratio. The primary endpoint was the morbidity and mortality within 30 postoperative days to evaluate the surgical safety of LADG. The secondary endpoint was 3-year disease-free survival. This trial was registered at ClinicalTrial.gov as NCT02464215.

Results Between March 2014 and August 2017, a total of 446 patients with cT2-4aN0-3M0 (AJCC 7th staging system) were enrolled. Of these, 222 patients underwent LADG and 220 patients underwent ODG were included in the modified intention-to-treat analysis. The compliance rate of D2 lymph node dissection was identical between the LADG and ODG arms (99.5%, \( P = 1.000 \)). No significant difference was observed regarding the overall postoperative complication rate in two groups (LADG 13.1%, ODG 17.7%, \( P = 0.174 \)). No operation-related death occurred in both arms.

Conclusions This trial confirmed that LADG performed by credentialed surgeons was safe and feasible for patients with AGC compared with conventional ODG.

Keywords Locally advanced gastric cancer · Laparoscopy-assisted distal gastrectomy · Open distal gastrectomy · Surgical outcomes · Clinical trial

Gastric cancer is the fifth most common malignancy, and the third leading cause of cancer death worldwide [1]. Nearly two-thirds of all gastric cancer cases occur in East/Southeast and Central Asia, with 63% cases diagnosed as non-cardia gastric cancer topographically [2]. Because of unhealthy eating habits and infrequent gastroscopic examination, China accounts for 42.6% and 45.0% of the global gastric cancer incidence and mortality, respectively [3]. More than 80% Chinese patients are diagnosed with locally advanced gastric cancer. Among them, almost 60% cases exhibit a single lesion located at the distal stomach [2], thus requiring distal gastrectomy with D2 lymphadenectomy as standard treatment according to the Japanese gastric cancer treatment guidelines [4].

Due to some definite benefits of the minimally invasive surgery, for instance, alleviated pain, shortened hospital stay, and reduced blood loss, laparoscopy-assisted distal gastrectomy has gained growing popularity in China, Japan, and South Korea. Some well-designed multicenter randomized...
controlled trials (RCTs) from Japan (JCOG0912 [5]) and Korea (KLASS-01 [6]) revealed that LADG was just as safe as conventional ODG in terms of short-term clinical outcomes for stage I gastric cancer, even with significantly lower overall complication rate [6]. Furthermore, the long-term outcomes of EGC patients undergoing LADG were proven comparable to those of patients treated by ODG from a single-arm, multi-institutional clinical trial (JCOG0703 [7]).

Despite the broad application of laparoscopic surgery, whether patients with AGC can benefit from this minimally invasive approach as patients with EGC remains controversial. Owing to several limitations of LADG such as relatively narrow surgical vision, impossible palpation, and more complicated laparoscopic procedures when performing D2 lymph node dissection, operative safety cannot be ensured except skilled surgeons. Besides, the reports of port site seeding and metastases by laparoscopy in the treatment of urinary as well as reproductive system tumors [8–10], and the lack of long-term survival evidence all put the application of LADG for AGC in a challenge.

Around the year 2014, several retrospective studies conducted in East Asia have reported that the application of laparoscopic gastrectomy neither increased surgical risk nor shortened the disease-free survival in AGC patients [11–13]. Further, CLASS-01 in China [14] and JLSSG0901 [15] in Japan have launched nationwide, multi-institutional, two-arm RCTs respectively to compare the safety and efficacy of LADG to ODG for AGC patients. With the wide acceptance of minimally invasive concept, more and more surgeons in North China have completed the learning curve. They found that the fatness degree of patients might influence some detailed surgical procedures when performed LADG. People in North China are more obese than those in the South due to the economic, climate and regional differences [16–18]. According to the epidemiologic survey by He et al., the prevalence of overweight and obesity in rural North China is nearly two-fold as much as that in the South (43.5% vs. 24.8%) [18]. Since obesity is one of the essential factors affecting surgical performance [19, 20], analysis of patients in the northern part of the Chinese mainland will be more instructive for surgeons in this area. Besides, before extensive application of a new surgical technique, the operative safety should be guaranteed first.

Therefore, a multicenter, two-arm, randomized study was launched to investigate the non-inferiority of LADG with D2 lymphadenectomy to ODG in terms of operative safety for locally AGC in North China. And the short-term outcomes are reported herein.

### Patients and methods

#### Study design

This study was designed as a multicenter, open-label, non-inferiority, parallel, prospective RCT conducted at five high-volume university hospitals with nine surgeons in Beijing, China. Before initiating this study, the study protocol was approved by the independent ethics committee or institutional review board of each participating institution. This trial was registered with ClinicalTrial.gov (NCT02464215).

The primary endpoint of this clinical trial was the postoperative morbidity and mortality within 30 days. The second endpoint was 3-year disease-free survival. The preoperative staging was evaluated comprehensively by thoracic, abdominal and pelvic computed tomography scans as well as endoscopic ultrasonography of the gastric lesion. All candidates involved in this trial provided written informed consent.

#### Patient eligibility

The inclusion criteria for enrolling patients were as follows: Patients age older than 18 years (including 18 years old); Pathologically confirmed primary gastric adenocarcinoma by endoscopic biopsy (including papillary, tubular, mucinous, signet ring cell, and poorly differentiated adenocarcinoma); Tumor located in the lower part of the stomach, potentially resectable by subtotal gastrectomy and D2 lymph node dissection; Preoperative cancer stage cT2-4aN0-3M0 (according to AJCC-7th TNM staging); The Eastern Cooperative Oncology Group performance status of 0 or 1, or the American Society of Anesthesiology classes of I, II, or III; Signed Informed consent.

The exclusion criteria were listed as follows: Surgical history of upper abdomen (except laparoscopic cholecystectomy); Previous gastrectomy, including endoscopic submucosal dissection and endoscopic mucosal resection; Integrated or enlarged lymph node with maximum diameter larger than 3 cm according to preoperative imaging; Other malignant diseases (within 5 years); Preoperative chemotherapy, immunotherapy or radiotherapy; Other illnesses needed operation concurrently; Complications (bleeding, perforation, or obstruction) required emergency surgery due to primary gastric malignancy; Pulmonary function tests FEV1 less than 50% of predicted value; Patient suffered from bleeding tendency disease such as hemophilia or took anti-coagulant medication due to deep vein thrombosis.
Randomization and masking

As soon as the informed consent was obtained from patients, these eligible patients were assigned to LADG or ODG groups randomly with a 1:1 allocation ratio according to a computer-generated randomization list. The randomization was carried out centrally by the contract research organization (CRO, Beijing High-land Med-Tech Development, Beijing, China), and was not masked for both participating surgeons and patients. The whole process of this trial was monitored by the CRO mentioned above, as well.

Quality control

All surgeons involved in this trial were specialized in gastric surgery, and have already conducted at least 60 ODG and 60 LADG with D2 lymphadenectomy previously. Each participating institute could perform at least 80 gastrectomies for advanced gastric cancer patients each year. Intraoperative photographs and unedited videos were mandatory required and monitored by the study chair to control the surgical quality. Ten photos were uploaded for each participant. Among them, five pictures were taken for lymph node dissection fields, four for the lesion and resection margins of specimens, and one for the abdominal incision.

Interventions and outcome measurements

With the exception of surgical approach, all procedures of LADG and ODG group were identical. General anesthesia and tracheal intubation were used during operation in all patients. The location of trocars was not limited while the number should be less than five in the LADG group. After confirmed no metastasis in the abdominal cavity and assessed the resectability of the lesion by laparoscopic exploration, gastrectomy was performed with total omentectomy. The extent of lymphadenectomy adhered principles of Japanese gastric cancer treatment guidelines, as well [4]. Reconstruction was not limited in this trial. Surgeons performed standard Billroth-I (B-I), Billroth-II (B-II), or Roux-en-Y fashion according to their preferences. In the LADG arm, only one mini-laparotomy incision less than 10 cm was permitted.

All the surgical- and medical-related adverse events were documented in detail postoperatively. Wound problems referred to seroma, hematoma, wound infection, and wound dehiscence which occurred on surgery wound and needed additional treatment. Intra-abdominal abscess was confirmed by ultrasonography or tomography, with an increase in WBC and temperature. Anastomotic leakage was defined as gastric contents leaked through drainage tube or proven by upper gastrointestinal tomography. Gastroparesis referred to the obstructed passing of foods through the anastomotic part, with no opinions of intestinal obstruction, stenosis, leakage, or peritonitis. Pancreatic fistula is described as any measurable volume of drain fluid with amylase activity greater than 3 times the upper normal serum value on or after postoperative day 3 [21]. Pulmonary complications were proven by chest X-ray, with symptoms of fever, increased WBC, or even difficulty in breathing. The severity of postoperative morbidity was assessed based on the Clavien–Dindo classification [22].

Sample size

In order to evaluate the surgical safety of LADG, the overall postoperative complication rate was set as the primary end-point of this trial. According to the previous reports of Degiuli, the total morbidity rate of standard gastrectomy with D2 lymph node dissection was estimated at 16.3% [23, 24], and the margin of non-inferiority was assumed to be 10%. With a type I error of 0.025 (one-sided) and 80% power, 220 patients were required per group. The sample size was calculated by using PASS11 (NCSS, East Kaysville, UT, USA).

Statistics

Continuous variables were expressed as the mean ± standard deviation, and categorical variables were presented as frequencies along with percentages. The differences between groups were tested by Student t test, χ² or Fisher’s exact test where appropriate. The relative risk with 95% confidence interval (CI) for the intraoperative and postoperative complication rates of the LADG group was calculated relative to the reference group. A multivariate binary logistic regression analysis was conducted to determine independent risk factors for postoperative morbidity. All P values were two-sided, and P values less than 0.05 were considered statistically significant. All statistical analyses were conducted with SPSS (Version 20.0 for Windows; SPSS Inc., Chicago, IL).

Results

Between March 2014 and August 2017, 446 patients were enrolled from 5 high-volume specialized hospitals in Beijing and were randomly assigned to the LADG or ODG group evenly (n = 223 per group). Of these, a total of four patients were excluded after randomization. In the LADG arm, one patient was excluded due to the previous diagnosis of gastric cancer could not be confirmed by endoscopic biopsy at the participating hospital. In the ODG arm, three patients were excluded: one patient withdrew his consent, and other two patients who strongly preferred minimal invasive surgery refused the assigned surgery (Fig. 1). Clinical data of 222
patients in the LADG group and 220 patients in the ODG group were collected thoroughly and entered into an electronic Case Report Form (https://apps.bmclinsys.com/hldcro/MainFrame.aspx) to analyze surgical outcomes.

The clinical and pathological characteristics of involved patients are listed in Table 1. The mean age was 59.4 years in the LADG arm and 60.6 years in the ODG arm, with the male-to-female ratio of approximately 2:1 in each group. Other baseline factors including BMI, ASA score, comorbidities, tumor location, tumor size, histological type and the pathological stages were all well balanced between these two groups.

![CONSORT diagram](image-url)
Table 1  Patient baseline and pathological characteristics

| Characteristics                      | LADG group (n = 222) | ODG group (n = 220) | P   |
|--------------------------------------|----------------------|--------------------|-----|
|                                      | No. %                | Mean SD            | No. % | Mean SD |        |
| Sex                                  |                      |                    |      |         | 0.338  |
| Male                                 | 144 64.9             | 59.4 12.4          | 133 60.5 |
| Female                               | 78 35.1              | 60.6 10.2          | 87 39.5 |
| Age (years)                          |                      |                    |      |         | 0.291  |
| BMI (kg/m²)                          | 23.1 3.1             |                    | 23.5 3.3 |
| ASA score                            |                      |                    |      |         | 0.209  |
| I                                    | 96 43.2              | 60.6 10.2          | 83 37.7 |
| II                                   | 124 55.9             |                    | 131 59.5 |
| III                                  | 2 0.9                | 6 2.7              |        |
| No. of comorbidities                 |                      |                    |      |         | 0.485  |
| 0                                    | 152 68.5             | 157 71.4           |      |
| 1                                    | 47 21.2              | 50 22.7            |      |
| 2                                    | 18 8.1               | 10 4.5             |      |
| ≥3                                   | 5 2.3                | 3 1.4              |      |
| Comorbidity                          |                      |                    |      |         |        |
| Diabetes                             | 22 9.9               | 19 8.6             |      |
| CVD                                  | 16 7.2               | 8 3.6              |      |
| Hypertension                         | 46 20.7              | 38 17.3            |      |
| COPD                                 | 0 0                  | 2 0.9              |      |
| Hepatic                              | 0 0                  | 1 0.5              |      |
| Renal                                | 1 0.5                | 0 0                |      |
| Cerebrovascular                      | 2 0.9                | 1 0.5              |      |
| Others                               | 14 6.3               | 11 5.0             |      |
| Tumor size (cm)                      | 3.6 1.8              | 3.9 2.2            | 0.106|
| Histology                            |                      |                    |      |         | 0.164  |
| Differentiated                       | 47 21.2              | 59 26.8            |      |
| Undifferentiated                     | 175 78.8             | 161 73.2           |      |
| Tumor location                       |                      |                    |      |         | 0.865  |
| Upper                                | 2 0.9                | 2 0.9              |      |
| Middle                               | 29 13.1              | 35 15.9            |      |
| Lower                                | 181 81.5             | 173 78.6           |      |
| Whole                                | 10 4.5               | 10 4.5             |      |
| Pathological T stage<sup>a</sup>     |                      |                    |      |         | 0.656  |
| T1                                   | 58 26.1              | 52 23.6            |      |
| T2                                   | 45 20.3              | 35 15.9            |      |
| T3                                   | 65 29.3              | 71 32.3            |      |
| T4a                                  | 49 22.1              | 57 25.9            |      |
| T4b                                  | 5 2.3                | 5 2.3              |      |
| Pathological N stage<sup>a</sup>     |                      |                    |      |         | 0.662  |
| N0                                   | 100 45.0             | 93 42.3            |      |
| N1                                   | 43 19.4              | 43 19.5            |      |
| N2                                   | 30 13.5              | 39 17.7            |      |
| N3                                   | 49 22.1              | 45 20.5            |      |
| Pathological M stage<sup>a</sup>     |                      |                    |      |         | 0.543  |
| M0                                   | 218 98.2             | 214 97.3           |      |
| M1                                   | 4 1.8                | 6 2.7              |      |
| Pathological TNM stage<sup>a</sup>   |                      |                    |      |         | 0.982  |
| IA                                   | 44 19.8              | 41 18.6            |      |
| IB                                   | 31 14.0              | 27 12.3            |      |
The surgical outcomes are summarized in Table 2. Distal gastrectomy was carried out for 214 patients (96.4%) in the LADG group and 204 patients (92.7%) in the ODG group ($P = 0.089$). About 99.5% participants underwent D2 lymphadenectomy in the LADG group, so did patients in the ODG group ($P = 1.000$). The reconstruction methods performed by surgeons were comparably distributed in each group, as well ($P = 0.149$). With respect to the mean surgical time, the LADG group took 32.6 min longer than the ODG group (242.5 ± 63.5 vs. 209.9 ± 53.6, $P < 0.001$). And the estimated blood loss in the LADG group was 26.1 mL less than the blood loss in the ODG group (91.4 ± 90.9 vs. 117.5 ± 103.5, $P = 0.005$). During operation, 14 patients in the LADG group underwent open conversion because of locally advanced tumors which invaded surrounding organs ($n = 6$), uncontrolled bleeding ($n = 2$), dense adhesions blurred the surgical field ($n = 4$), and length of incision more than 10 cm ($n = 2$). Concerning the recovery process, patients in the LADG group got a shorter duration to first flatus ($P = 0.013$), a much earlier first liquid intake ($P = 0.003$), and a less postoperative hospital stay ($P = 0.018$) compared with patients in the ODG group. There was no significant difference with regard to intraoperative blood transfusion rate ($P = 0.984$), the length to the proximal ($P = 0.169$) or distal ($P = 0.501$) resection margin, time to ambulation ($P = 0.274$), and the retrieved lymph nodes ($P = 0.083$) between the two arms.

Surgery-related complications are presented in Table 3. Intraoperative adverse events happened in five patients (2.3%) in the LADG group (more than 400 mL bleeding in three patients, spleen injury in one patient and diaphragm injury in one patient), and six patients (2.7%) in the ODG group (more than 400 mL bleeding in five patients and transfusion allergic reaction in one patient). In terms of overall postoperative morbidity within 30 days, no marked significance was observed between the LADG and ODG arms (13.1% vs. 17.7%, $P = 0.174$). Besides, each subtype of complication was distributed similarly in the two groups. No intraoperative or postoperative death happened in either group. The leading causes of postoperative adverse events were composed of the pulmonary problem, gastroparesis, and anastomotic leakage. Moreover, four patients in the LADG group and eight patients in the ODG group underwent reoperation due to anastomotic leakage (three vs. four), intestinal fistula (one vs. zero), intraluminal bleeding (zero vs. one), intra-abdominal bleeding (zero vs. two), and pancreatic fistula (zero vs. one).

Furthermore, univariate and multivariate analyses were conducted to distinguish risk factors which may influence the occurrence of postoperative morbidity. As shown in Table 4, the operative approach, number of comorbidities, type of reconstruction, operative time, and the pathological stage had no significant effect on the development of postoperative complications. Meanwhile, the age (OR ≥ 60 2.362, 95% CI 1.236–4.512; $P = 0.009$) and BMI (OR ≥ 25 2.013, 95% CI 1.101–3.680, $P = 0.023$) were identified as independent risk factors for postoperative complications through multivariate analysis.

We further analyzed the association between BMI and surgical complications in each group, and the results are listed in Table 5. The proportion of postoperative morbidity was lower in the subset of BMI < 25, compared with the subgroup of BMI ≥ 25 in the LADG group (9.3% vs. 23.3%, $P = 0.006$). While in the ODG group, the rate of postoperative morbidity was similar no matter whether BMI < 25 or ≥ 25 (16.9% vs. 20.0%, $P = 0.589$).

**Discussion**

With the acceptance of minimally invasive concept, whether gastric cancer patients could benefit from the application of laparoscopy has attracted more and more attention. As LADG is upgraded from an investigational treatment to

---

**Table 3** (continued)

| Characteristics | LADG group ($n = 222$) | ODG group ($n = 220$) | $P$ |
|-----------------|------------------------|-----------------------|-----|
| No. | % | Mean | SD | No. | % | Mean | SD |
| IIA | 31 | 14.0 | | 31 | 14.1 | |
| IIB | 32 | 14.4 | | 32 | 14.5 | |
| IIIA | 32 | 14.4 | | 28 | 12.7 | |
| IIIB | 28 | 12.6 | | 32 | 14.5 | |
| IIIC | 20 | 9.0 | | 23 | 10.5 | |
| IV  | 4  | 1.8  | | 6 | 2.7 | |

LADG laparoscopy-assisted distal gastrectomy, ODG open distal gastrectomy, SD standard deviation, BMI body mass index, ASA American society of anesthesiologists, CVD cardiovascular disease except hypertension, COPD chronic obstructive pulmonary disease

*Pathologic stage according to the American Joint Committee on Cancer, 7th Edition*
an optional therapy for clinical stage I GC after years of practice [25], various studies have concerned the feasibility and safety of LADG for patients with AGC. A majority of research compared LADG with ODG were retrospective studies [11–13]. What is more, conclusions from retrospective or prospective studies even meta-analyses [26, 27] concerning this topic were inconsistent. Some literature concluded that LADG was associated with a lower postoperative complication rate in AGC patients [26, 27]; others found no significant difference between LADG and ODG concerning postoperative morbidity [14, 28]. Even a meta-analysis reported by Cochrane Database considered that the evidence qualities of most completed or ongoing RCTs were low because of high risks of bias [29]. Since operative safety is an essential prerequisite and basis for new surgical procedures, well-designed trials are needed to validate the safety and efficacy of LADG for AGC patients.

The present RCT, which recruited patients from North China with unrestricted BMI and upper age limit, therefore partially represented the real-world data, showed no remarkable difference between LADG and ODG regarding postoperative morbidity. The well-known advantages of LADG reported in EGC patients [5, 6], such as less blood loss and faster postoperative recovery was confirmed in this

| Table 2 Surgical outcomes of the LADG and ODG groups |
|-----------------------------------------------|
| Outcomes                        | LADG group (n = 222) | ODG group (n = 220) | P* |
| No. | % | Mean | SD | No. | % | Mean | SD |
|-----------------------------------------------|
| Gastrectomy                               |                        |                        |    |
| Distal                                    | 214 | 96.4 | 204 | 92.7 | 0.089b |
| Total                                     | 8 | 3.6 | 16 | 7.3 |    |
| Reconstruction                            |                        |                        |    |
| Billroth-I                                 | 97 | 43.7 | 90 | 40.9 | 0.149b |
| Billroth-II                                | 105 | 47.3 | 97 | 44.1 |    |
| Roux-en-Y                                  | 19 | 8.6 | 33 | 15.0 |    |
| Others                                    | 1 | 0.5 | 0 | 0 |    |
| Lymphadenectomy                           |                        |                        |    |
| D2                                         | 221 | 99.5 | 219 | 99.5 | 1.000c |
| Others                                     | 1 | 0.5 | 1 | 0.5 |    |
| Combined resection                        | 1 | 0.5 | 4 | 1.8 | 0.215c |
| Partial liver                             | 0 | 0 | 2 | 0.9 |    |
| Spleen                                    | 0 | 0 | 1 | 0.5 |    |
| Partial transverse colon or mesentery     | 1 | 0.5 | 1 | 0.5 |    |
| Surgical time (min)                       | 242.5 | 63.5 | 209.9 | 53.6 | 0.000 |
| Estimated blood loss (mL)                 | 91.4 | 90.9 | 117.5 | 103.5 | 0.005 |
| Open conversion                           | 14 | 6.3 |    |    |    |
| Locally advanced tumor (T4 stage)         | 6 |    |    |    |    |
| Uncontrolled bleeding                     | 2 |    |    |    |    |
| Adhesion                                  | 4 |    |    |    |    |
| Length of incision > 10 cm                | 2 |    |    |    |    |
| Intraoperative blood transfusion          | 9 | 4.1 | 9 | 4.1 | 0.984b |
| Proximal resection margin (cm)            | 5.0 | 2.2 | 5.3 | 2.5 |    |
| Distal resection margin (cm)              | 3.8 | 2.4 | 3.9 | 2.7 | 0.501 |
| Retrieved lymph nodes                     | 29.5 | 10.4 | 31.4 | 12.3 | 0.083 |
| Length of incision (cm)                   | 8.1 | 3.7 | 16.7 | 3.8 | 0.000 |
| Time to ambulation (days)                 | 1.2 | 1.0 | 1.4 | 1.8 | 0.274 |
| Time to first flatus (days)               | 2.8 | 1.0 | 3.1 | 1.4 | 0.013 |
| Time to first liquid intake (days)        | 7.0 | 1.8 | 7.9 | 3.7 | 0.003 |
| Postoperative hospital stay (days)        | 9.9 | 3.7 | 10.9 | 5.2 | 0.018 |

LADG laparoscopy-assisted distal gastrectomy, ODG open distal gastrectomy, SD standard deviation

*Student t test
**Pearson Chi-square test
***Fisher’s exact method
Due to the magnified surgical field and more meticulous surgical procedures, unexpected bleeding and excessive distraction could be prevented efficiently. Patients in both arms were forced to resume off-bed activities the day after the operation, which contributed to the similar time to ambulation shown in Table 2.

The overall postoperative complication rate in our study was comparable to the morbidity reported by the nationwide CLASS-01 trial in China [14]. Pulmonary complications accounted for the most considerable proportion of postoperative adverse events. Advanced age, cardiac and pulmonary comorbidities, reduced diaphragmatic activity due to incisional pain and microatelectasis were possible reasons led to such complications [30, 31].

Different from CLASS-01, gastroparesis was also another leading cause of postoperative adverse events. The incidence of gastroparesis in this trial was comparable to the previous reports of 0.4–7% [6, 14, 32–34]. The etiology of postsurgical gastroparesis syndrome (PGS) was diverse. Recent studies identified several risk factors for PGS, such as patient BMI ≥ 25 kg/m², age ≥ 65 years, B-II reconstruction and the like [33, 35]. In the present study, PGS occurred in 16 patients in total. Among them, the BMI of eight patients was higher than 25 kg/m², with three of them even higher than 30 kg/m² (BMI < 25 vs. ≥ 25, 2.5% vs. 6.7%, P = 0.046); the age of seven patients was older than 65 years (Age < 65 vs. ≥ 65, 3.1% vs. 4.5%, P = 0.446); and eight of them received B-II construction (B-II vs. non-B-II, 4.0% vs. 3.3%, P = 0.725). Although the number of patients with PGS was not enough for us to draw definite conclusions, obesity partially contributed to the incidence of PGS in our study.

As for the conversion rate from LADG to ODG, the proportion present in this trial was similar to that reported in CLASS-01 (6.4%) [14], but was higher than that seen in KLASS-01 (3.2%) [6], JCOG0912 (3.5%) [5], and JCOG0703 (2.9%) [36]. One potential reason might be the locally advanced tumors (T4) which invaded surrounding organs and were difficult to handle through laparoscopy in AGC patients. Besides, surgeons intended to achieve the same surgical quality as obtained from ODG for the sake of patient’s benefit.

Similar as the results from CLASS-01 and KLASS-01 trials [6, 14], the incidences of pancreatic fistula and the severe morbidity rate which referred to postoperative complications no less than grade IIIa according to the Clavien-Dindo classification [22] were both relatively low in our

### Table 3 Morbidity and mortality in the LADG and ODG groups within 30 postoperative days

| Morbidity type              | LADG group (n = 222) | ODG group (n = 220) | P  | RR (95% CI) |
|-----------------------------|----------------------|---------------------|----|-------------|
| No. | %  | No. | %  |
| Intraoperative complication | 5 | 2.3 | 6 | 2.7 | 0.749 | 0.826 (0.256–2.666) |
| Postoperative complication  | 29 | 13.1 | 39 | 17.7 | 0.174 | 0.737 (0.473–1.148) |
| Wound problem               | 3 | 1.4 | 2 | 0.9 | 1.000 | 1.486 (0.251–8.810) |
| Fluid collection/abscess    | 2 | 0.9 | 4 | 1.8 | 0.448 | 0.495 (0.092–2.678) |
| Intra-abdominal bleeding    | 0 | 0 | 2 | 0.9 | 0.247 | |
| Intraluminal bleeding       | 1 | 0.5 | 2 | 0.9 | 0.622 | 0.495 (0.045–5.425) |
| Ileus                       | 1 | 0.5 | 2 | 0.9 | 0.622 | 0.495 (0.045–5.425) |
| Intestinal fistula          | 1 | 0.5 | 0 | 0 | 1.000 | |
| Anastomotic leakage         | 3 | 1.4 | 4 | 1.8 | 0.723 | 0.743 (0.168–3.282) |
| Lymphatic leakage           | 2 | 0.9 | 3 | 1.4 | 0.685 | 0.661 (0.111–3.915) |
| Gastroparesis               | 6 | 2.7 | 10 | 4.5 | 0.322 | 0.595 (0.220–1.608) |
| Pancreatic fistula          | 0 | 0 | 1 | 0.5 | 0.498 | |
| Pulmonary problem           | 10 | 4.5 | 8 | 3.6 | 0.811 | 1.239 (0.498–3.080) |
| Renal problem               | 0 | 0 | 1 | 0.5 | 0.498 | |
| Mortality                   | 0 | 0 | 0 | 0 | |
| Clavien–Dindo classification| | | | | 0.780 |
| I                           | 3 | 1.4 | 2 | 0.9 | 1.000 | 1.486 (0.251–8.810) |
| II                          | 21 | 9.5 | 28 | 12.7 | 0.292 | 0.743 (0.436–1.268) |
| IIIa                        | 1 | 0.5 | 1 | 0.5 | 1.000 | 0.991 (0.062–15.744) |
| IIIb                        | 4 | 1.8 | 8 | 3.6 | 0.259 | 0.495 (0.151–1.622) |
| IV                          | 0 | 0 | 0 | 0 | |

LADG laparoscopy-assisted distal gastrectomy, ODG open distal gastrectomy

aFisher’s exact method

bPearson Chi-square test
Table 4  Univariate and multivariate analyses of risk factors for postoperative complications

| Variables                     | No. (n = 442) | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------|---------------------|-----------------------|
|                               |               | Morbidity (n = 68)  | Odds ratio<sup>a</sup> |
| Operative approach            |               |                     |                       |
| Laparoscopy                   | 222           | 29 (13.1%)          |                       |
| Open                          | 220           | 39 (17.7%)          |                       |
| Age (years)                   |               |                     |                       |
| < 60                          | 189           | 18 (9.5%)           |                       |
| ≥ 60                          | 253           | 50 (19.8%)          |                       |
| Sex                           |               |                     |                       |
| Male                          | 277           | 48 (17.3%)          |                       |
| Female                        | 165           | 20 (12.1%)          |                       |
| BMI (kg/m²)                   |               |                     |                       |
| < 25                          | 322           | 42 (13.0%)          |                       |
| ≥ 25                          | 120           | 26 (21.7%)          |                       |
| No. of comorbidities          |               |                     |                       |
| 0                             | 309           | 42 (13.6%)          |                       |
| 1                             | 97            | 18 (18.6%)          |                       |
| 2                             | 28            | 7 (25.0%)           |                       |
| ≥ 3                           | 8             | 1 (12.5%)           |                       |
| Reconstruction type           |               |                     |                       |
| Billroth-I                    | 187           | 22 (11.8%)          |                       |
| Billroth-II                   | 202           | 34 (16.8%)          |                       |
| Roux-en-Y                     | 53            | 12 (22.6%)          |                       |
| Operative time (min)          |               |                     |                       |
| ≤ 200                         | 180           | 24 (13.3%)          |                       |
| > 200                         | 262           | 44 (16.8%)          |                       |
| Pathological T stage<sup>b</sup> |           |                     |                       |
| T1                            | 110           | 15 (13.6%)          |                       |
| T2                            | 80            | 10 (12.5%)          |                       |
| T3                            | 136           | 24 (17.6%)          |                       |
| T4                            | 116           | 19 (16.4%)          |                       |
| Pathological N stage<sup>b</sup> |           |                     |                       |
| N0                            | 193           | 23 (11.9%)          |                       |
| N1-3                          | 249           | 45 (18.1%)          |                       |
| Pathological TNM stage<sup>b</sup> |         |                     |                       |
| I                             | 143           | 17 (11.9%)          |                       |
| II                            | 126           | 16 (12.7%)          |                       |
| III                           | 163           | 32 (19.6%)          |                       |
| IV                            | 10            | 3 (30%)             |                       |

BMI body mass index
<sup>a</sup>The 95% confidence interval was given in parentheses
<sup>b</sup>Pathologic stage according to the American Joint Committee on Cancer, 7th Edition

Table 5  The analysis of BMI and postoperative morbidity in the LADG or ODG group

| BMI (kg/m²) | LADG group | ODG group |
|-------------|------------|-----------|
|             | No. (n = 222) | Morbidity (n = 29) | P    | No. (n = 220) | Morbidity (n = 39) | P    |
| < 25        | 162        | 15 (9.3%)  | 0.006 | 160        | 27 (16.9%)  | 0.589 |
| ≥ 25        | 60         | 14 (23.3%) |       | 60         | 12 (20.0%)  |       |

LADG laparoscopy-assisted distal gastrectomy, ODG open distal gastrectomy, BMI body mass index
study. The definition of postoperative pancreatic fistula (POPF) which we followed in the present trial has been updated in 2016 by the International Study Group of Pancreatic Fistula (ISGPF) [21]. Compared with the definition of POPF in 2005 [37], increased amylase activity without clinical impact was defined as biochemical leak rather than pancreatic fistula. Besides, operations performed by credentialed surgeons were much more meticulously. Therefore, less complications of pancreatic fistula were recorded in our study. The Clavien–Dindo classification defines the severity of surgical complications according to the type of corresponding therapy [22]. If the treatment of postoperative morbidity does not require surgical, endoscopic or radiological intervention, the severity classification of postoperative morbidity will be less than grade III [22]. Take anastomotic leakage for example, if the patient needs reoperation, the Clavien–Dindo grade is IIIb; if the subject needs percutaneous drainage treatment, the grade is IIIa. While if only long-term total parenteral nutrition and fasting can alleviate this complication, it will be leveled as grade II. As Lee et al. described, one of the most important risk factors for laparoscopic gastrectomy is the experience of the surgeon [38]. All participated surgeons in our study have completed the learning curve and were full of experience. Furthermore, with the continuous improvement of perioperative nursing care and the practice guided by the concept of Enhanced Recovery After Surgery (ERAS), severe surgical complications are getting less and less.

Moreover, the mean retrieved lymph nodes were comparable in two arms in our study (LADG vs. ODG: 29.5 ± 10.4 vs. 31.4 ± 12.3, P = 0.083), which was in the range of 23.0–43.3 as reported previously [6, 39, 40], but slightly less than that presented in CLASS-01 [14]. The number of harvested lymph nodes was not only associated with the surgical technique but also correlated with the thoroughness of pathological examination, state of specimens and the innate number of lymph nodes for each patient [39]. In China, experienced surgeons after learning curve could harvest 26.2–28.8 LNs in D2 lymphadenectomy [41, 42]. Although some recent studies suggested that higher retrieved lymph nodes could lead to better prognosis in gastric cancer patients [43], Lu indicated that still at least 16 removed lymph nodes could yield improved prognosis of patients underwent distal gastrectomy [39]. As a multicenter trial, we considered that the retrieved lymph nodes were sufficient in our study.

Because of increased life expectancy and a better quality of life, the number of gastric cancer patients with advanced age and higher BMI is continuously rising, especially in the north part of China [44]. Previous reports indicated that elder age and high BMI contributed to increased morbidity after gastrectomy [45–47]. Similarly, gastric cancer patients who were more than 60 years or BMI higher than 25 kg/m² had a greater risk of postoperative complications in this trial. Regarding the effect of BMI on the surgical results of LADG, we found that higher BMI was a risk factor for the occurrence of complications in the LADG group but not in the ODG group. Compared with ODG, performing LADG in AGC patients with higher BMI is much more difficult due to insufficient visualization of the abdominal cavity. As reported by Noshiro et al. [47], in order to improve the visualization field in fatty patients, surgeons have to use higher insufflation pressure or rotate the operative table extremely when performing LADG, which may cause increased accidental injuries during operation. In addition, because it is harder to isolate blood vessels or dissect lymph nodes which are surrounded by a massive bulk of fat tissues under laparoscopy, the prolonged surgical time and anesthesia duration may lead to more postoperative complications in obese patients. Currently, several studies including ours believed that the proportion of postoperative adverse events might be increased with higher BMI when conducting LADG [47, 48], while a few other groups considered that increased BMI could not raise the likelihood of postoperative morbidity yet [49, 50]. Therefore, whether or not increased BMI influences the surgical results of patients undergoing LADG requires more substantial evidence to draw conclusions.

There were several limitations in the present study. First, few hospitals from other provinces in North China had participated in this multicenter clinical trial. Second, selection bias might existed since the randomization of surgical process was not done in the operating room. At last, besides BMI, a more sophisticated method such as visceral fat area should be applied to evaluate obesity, and thus more accurate results could be obtained to reveal the effect of obesity on the surgical results of LADG. Based on the results of the present study, we are planning to perform a randomized phase-III trial to compare the oncologic efficacy between LADG and ODG, and designs aimed at investigating the effect of obesity are included, as well.

In summary, the results of this RCT demonstrated that LADG performed by credentialed surgeons was surgically safe and feasible for AGC patients compared with conventional ODG. Nevertheless, before the non-inferiority of LADG with regard to oncologic efficacy is generally confirmed, laparoscopic surgery is still an investigational treatment for AGC [25], which needs to be carefully performed under well-established principles.

Acknowledgements The authors are grateful for the statistics-related consultation provided by Dr. Yingjian He.

Funding This study was supported by the grants from Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (No. XM201309 and No. ZYLYX201701), Capital’s Funds for Health Improvement and Research (CFH 2018-2-2153), Beijing Municipal Natural Science Foundation (No. 7162039,
No. 7172042, and No. 7132054), National Natural Science Foundation of China (No. 81272766, No. 81450028, No. 81672439, No. 81402346, No.81470129, and No. 81502137), Science Foundation of Peking University Cancer Hospital (No. 2017-14), Beijing Municipal Administration of Hospitals Incubating Program (No. PX2016018), Beijing Health System High-level Health Technical Personnel Training Program (No.2015-3-074), and the Excellent Overseas-Returnee Scholar Program (Ministry of Education).

Compliance with ethical standards

Disclosures Drs. Zhaozao Wang, Jiadi Xing, Jun Cai, Zhongtao Zhang, Fei Li, Nengwei Zhang, Jixiang Wu, Ming Cui, Ying Liu, Lei Chen, Hong Yang, Zhi Zheng, Xiaohui Wang, Chongchong Gao, Zhe Wang, Qing Fan, Yanlei Zhu, Shulin Ren, Chenghui Zhang, Maoying Liu, Jiafu Ji and Xiangqian Su have no conflicts of interest or financial ties to disclose.

Ethical approval All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent Informed consent or substitute for it was obtained from all patients for their being included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108
2. Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I (2015) Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 64(12):1881–1888
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer 136(5):E359–E386
4. Japanese Gastric Cancer Association (2010) Gastric cancer treatment guideline 2010 (2010), 3rd edn. Kanehara, Tokyo
5. Katai H, Mizusawa J, Katayama H, Takagi M, Yoshikawa T, Fukagawa T, Terashima M, Misawa K, Teshima S, Koeda K, Nishio M, Saito Y, Fujitani Y, Kadono M, Sasaki M (2017) Short-term surgical outcomes from a phase III study of laparoscopic-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer 20(4):699–708
6. Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ (2016) Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg 263(1):28–35
7. Hiki N, Katai H, Mizusawa J, Nakamura K, Nakamori M, Yoshikawa T, Kojima K, Imamoto H, Ninomiya M, Kitano S, Terashima M (2017) Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703). Gastric Cancer. https://doi.org/10.1007/s10106-016-0687-0
8. Kais H, Hershkovitz Y, Sandbank J, Haley A (2014) Port site metastases in squamous cell carcinoma of the gallbladder. Isr Med Assoc J 16(3):177–179
9. Song J, Kim E, Mobley J, Vemana G, Tanagho Y, Vetter J, Bhayani S, Russo P, Fugita O, Yang SS, Iwamura M, Eigenshau RS (2014) Port site metastasis after surgery for renal cell carcinoma: harbinger of future metastasis. J Urol 192(2):364–368
10. Palomba S, Mandato VS, La Sala GB (2014) Isolated port-site metastasis after robotic hysterectomy for stage IIA endometrial adenocarcinoma. Obstet Gynecol 123(3):664
11. Hu Y, Ying M, Huang C, Wei H, Jiang Z, Peng X, Hu J, Du X, Wang B, Lin F, Xu J, Dong G, Mou T, Li G, Chinese Laparoscopic Gastrointestinal Surgery Study G (2014) Oncologic outcomes of laparoscopy-assisted gastrectomy for advanced gastric cancer: a large-scale multicenter retrospective cohort study from China. Surg Endosc 28(7):2048–2056
12. Shinohara T, Satoh S, Kanaya S, Ishida Y, Taniguchi K, Isogaki J, Inaba K, Yanaka G, Uyama I (2013) Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study. Surg Endosc 27(1):286–294
13. Gordon AC, Kojima K, Inokuchi M, Kato D, Sugihara K (2013) Long-term comparison of laparoscopy-assisted distal gastrectomy and open distal gastrectomy in advanced gastric cancer. Surg Endosc 27(2):462–470
14. Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo S, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G (2016) Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol 34(12):1350–1357
15. Etoh T, Shiroshita H, Shiraishi N, Kitano S, Inomata M (2016) Ongoing clinical studies of minimally invasive surgery for gastric cancer in Japan. Trans Gastroenterol Hepatol 1:31
16. Shankar B (2010) Obesity in China: the differential impacts of covariates along the BMI distribution. Obesity 18(8):1660–1666
17. Chen TJ, Modin B, Ji CY, Hjern A (2011) Regional, socioeconomic and urban-rural disparities in child and adolescent obesity in China: a multilevel analysis. Acta Paediatr 100(12):1583–1589
18. He Y, Pan A, Wang Y, Yang Y, Xu J, Zhang Y, Liu D, Wang Q, Shen H, Yan D, Peng Z, Hu FB, Ma X (2017) Prevalence of overweight and obesity in 15.8 million men aged 15–49 years in rural China from 2010 to 2014. Sci Rep 7(1):5012
19. Dhar DK, Kubota H, Tachibana M, Kotoh T, Tabara H, Masunaga R, Kohno H, Nagasue N (2000) Body mass index determines the success of lymph node dissection and predicts the outcome of gastric carcinoma patients. Oncology 59(1):18–23
20. Inagawa S, Adachi S, Oda T, Kawamoto T, Koike N, Fukao K (2000) Effect of fat volume on postoperative complications and survival rate after D2 dissection for gastric cancer. Gastric Cancer 3(3):141–144
21. Bassi C, Marchegiani G, Gervenis C, Sary M, Abu Hilal M, Adhiam M, Allen P, Anderson R, Ashun HJ, Besselink MG, Conlon K, Del Chiaro M, Falconi M, Fernandez-Cruz L, Fernandez-Del Castillo C, Fingarot A, Friess H, Gouma DJ, Hackert T, Izbiicki J, Lillemoe KD, Neoptolemos JP, Olaa A, Schullack R, Shrikhande SY, Takada T, Takaori K, Traverso W, Vollmer CR, Wolfgang CL, Yeo CJ, Salvia R, Buchler M, International Study Group on Pancreatic S (2017) The 2016 update of the International Study
22. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213

23. Degiuli M, Sasaki M, Calgaro M, Garino M, Rebecchi F, Mineccia M, Scaglione D, Andreone D, Ponti A, Calvo F (2004) Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 30(3):303–308

24. Degiuli M, Sasaki M, Ponti A (2010) Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 97(5):643–649

25. Association JGC (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20(1):1–19

26. Zou ZH, Zhao LY, Mou TY, Hu YF, Yu J, Liu H, Chen H, Wu JM, An SL, Li GX (2014) Laparoscopic vs open D2 gastrectomy for locally advanced gastric cancer: a meta-analysis. World J Gastroenterol 20(44):16750–16764

27. Quan Y, Huang A, Ye M, Xu M, Zhuang B, Zhang P, Yu B, Min Z (2016) Comparison of laparoscopic versus open gastrectomy for advanced gastric cancer: an updated meta-analysis. Gastric Cancer 19(3):939–950

28. Inokuchi M, Nakagawa M, Tanioka T, Okuno K, Gokita K, Kojima K (2017) Long- and short-term outcomes of laparoscopic gastrectomy versus open gastrectomy in patients with clinically and pathologically locally advanced gastric cancer: a propensity-score matching analysis. Surg Endosc. https://doi.org/10.1007/s00464-017-5730-7

29. Best LM, Mughal M, Gurusamy KS (2016) Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database Syst Rev 3:CD011389

30. Nuttum R, Liu H, Zhen L, Hu YF, Mou TY, Lin T, I BA, Yu J, Li GX (2016) Risk factors for pulmonary complications following laparoscopic gastrectomy: a single-center study. Medicine 95(32):e4567

31. Inokuchi M, Kojima K, Kato K, Sugita H, Sugihara K (2014) Risk factors for post-operative pulmonary complications after gastrectomy for gastric cancer. Surg Infect 15(3):314–321

32. Meng H, Zhou D, Jiang X, Ding W, Lu L (2013) Incidence and risk factors for postsurgical gastroaparesis syndrome after laparoscopic and open radical gastrectomy. World J Surg Oncol 11:144

33. Liu DL, Zhang XW, Lyu FQ (2017) Analysis of risk factors for postsurgical gastroaparesis syndrome (PGS) after operation for gastric cancer. Zhonghua Zhong Liu Za Zhi 39(2):150–153

34. Dong K, Yu XJ, Li B, Wen EG, Xiong W, Guan QL (2006) Advances in mechanisms of postsurgical gastroaparesis syndrome and its diagnosis and treatment. Chin J Dig Dis 7(2):76–82

35. Chen XD, Mao CC, Zhang WT, Lin J, Wu RS, Zhang FM, Sun XW, Chi CH, Shen X, Wang PF (2017) A quantified risk-scoring system and rating model for postsurgical gastroaparesis syndrome in gastric cancer patients. J Surg Oncol 116(4):533–544

36. Kawai H, Sasaki M, Fukuda H, Nakamura K, Hiki N, Saka M, Yamaue H, Yoshikawa T, Kojima K (2010) Safety and feasibility of laparoscopic-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703). Gastric Cancer 13(4):238–244

37. Bassi C, Dervenis C, Batturini G, Fingerhut A, Yeo C, Izibicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M, International Study Group on Pancreatic Fistula D (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138(1):8–13

38. Lee JH, Park DJ, Kim HH, Lee HJ, Yang HK (2012) Comparison of complications after laparoscopy-assisted distal gastrectomy and open distal gastrectomy for gastric cancer using the Clavien-Dindo classification. Surg Endosc 26(5):1287–1295

39. Lu J, Wang W, Zheng CH, Fang C, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Huang CM, Zhou ZW (2017) Influence of total lymph node count on staging and survival after gastrectomy for gastric cancer: an analysis from a two-institution database in China. Ann Surg Oncol 24(2):486–493

40. Cai J, Wei D, Gao CF, Zhang CS, Zhang H, Zhao T (2011) A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer. Dig Surg 28(5–6):331–337

41. Wang W, Zheng C, Fang C, Li P, Xie J, Lin J, Zhan Y, Li W, Chen Y, Sun X, Xu D, Li Y, Huang C, Zhou Z (2015) Time trends of clinicopathologic features and surgical treatment for gastric cancer: results from 2 high-volume institutions in southern China. Surgery 158(6):1590–1597

42. Zhao LY, Zhang WH, Sun Y, Chen XZ, Yang K, Liu K, Chen XL, Wang YG, Song XH, Xue L, Zhou ZG, Hu JK (2016) Learning curve for gastric cancer patients with laparoscopy-assisted distal gastrectomy: 6-year experience from a single institution in western China. Medicine 95(37):e4875

43. Zhao B, Zhang J, Chen X, Sun T, Wang Z, Xu H, Huang B (2017) The retrieval of at least 25 lymph nodes should be essential for advanced gastric cancer patients with lymph node metastasis: a retrospective analysis of single-institution database study design: cohort study. Int J Surg 48:291–299

44. Liu J, Chen G, Chi I, Wu J, Pei L, Song X, Zhang L, Pang L, Han Y, Zheng X (2010) Regional variations in and correlates of disability-free life expectancy among older adults in China. BMC Public Health 10:446

45. Orsenigo E, Tomajer V, Palo SD, Carlucci M, Vignali A, Tamburini A, Staudacher C (2007) Impact of age on postoperative outcomes in 1118 gastric cancer patients undergoing surgical treatment. Gastric Cancer 10(1):39–44

46. Hamilton TD, Mahar AL, Haas B, Beyfuss K, Law CHL, Karanicolas PJ, Coburn NG, Hallet J (2017) The impact of advanced age on short-term outcomes following gastric cancer resection: an ACS-NSQIP analysis. Gastric Cancer. https://doi.org/10.1007/s10120-017-0786-6

47. Noshiro H, Shimizu S, Nagai E, Obuchida K, Tanaka M (2003) Laparoscopy-assisted distal gastrectomy for early gastric cancer: is it beneficial for patients of heavier weight? Ann Surg 238(5):680–685

48. Kawamura H, Tanioka T, Funakoshi T, Takahashi M (2011) Surgical effects of obesity on laparoscopy-assisted distal gastrectomy. Surg Laparosc Endosc Percutan Tech 21(3):155–161

49. Shim JH, Song KY, Kim SN, Park CH (2009) Laparoscopy-assisted distal gastrectomy for overweight patients in the Asian population. Surg Today 39(37):e4875

50. Makino H, Kunisaki C, Izumisawa Y, Tokuhisa M, Oshima T, Nagano Y, Fujii S, Kinuma J, Takagawa R, Kosaka T, Ono HA, Akiyama H, Endo I (2010) Effect of obesity on laparoscopy-assisted distal gastrectomy compared with open distal gastrectomy for gastric cancer. J Surg Oncol 102(2):141–147
Affiliations

Zaozao Wang¹ · Jiadi Xing¹ · Jun Cai² · Zhongtao Zhang² · Fei Li³ · Nengwei Zhang⁴ · Jixiang Wu⁵ · Ming Cui¹ · Ying Liu¹ · Lei Chen¹ · Hong Yang³ · Zhi Zheng² · Xiaohui Wang³ · Chongchong Gao³ · Zhe Wang³ · Qing Fan⁴ · Yanlei Zhu⁴ · Shulin Ren⁵ · Chenghai Zhang¹ · Maoxing Liu¹ · Jiafu Ji⁶ · Xiangqian Su¹

¹ Department of Gastrointestinal Surgery IV, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China
² Department of General Surgery, Beijing Key Laboratory of Cancer Invasion and Metastasis Research & National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
³ Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
⁴ Department of General Surgery, Peking University Ninth School of Clinical Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
⁵ Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Dongcheng, Beijing 100730, China
⁶ Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China